Pharmacielo Ltd Asset Resilience Ratio
Pharmacielo Ltd asset resilience ratio. Pharmacielo Ltd (PCLO) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PCLO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pharmacielo Ltd (2019–2023)
Asset resilience ratio of Pharmacielo Ltd from 2019 to 2023. This chart shows how Pharmacielo Ltd's Asset Resilience Ratio has changed over time. See PCLO free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Pharmacielo Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pharmacielo Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Pharmacielo Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Pharmacielo Ltd Industry Peers by Asset Resilience Ratio
Compare Pharmacielo Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Pharmacielo Ltd Asset Resilience Ratio by Year (2019–2023)
Pharmacielo Ltd asset resilience ratio by year from 2019 to 2023. The table below shows the annual Asset Resilience Ratio data for Pharmacielo Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$22.29 Million ≈ $16.12 Million |
-- |
| 2022-12-31 | 0.61% | CA$153.00K ≈ $110.68K |
CA$25.12 Million ≈ $18.17 Million |
-0.20pp |
| 2021-12-31 | 0.81% | CA$291.00K ≈ $210.50K |
CA$35.96 Million ≈ $26.01 Million |
-0.89pp |
| 2020-12-31 | 1.70% | CA$750.05K ≈ $542.57K |
CA$44.02 Million ≈ $31.85 Million |
+1.49pp |
| 2019-12-31 | 0.21% | CA$106.00K ≈ $76.68K |
CA$50.20 Million ≈ $36.31 Million |
-- |
About Pharmacielo Ltd
PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its… Read more